BeiGene starts Phase III of BGB-3111 in untreated CLL and SLL

BeiGene Ltd. (NASDAQ:BGNE) started a Phase III trial to evaluate twice-daily 80 mg BGB-3111 alone compared to Treanda bendamustine plus Rituxan rituximab in about 467 treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The primary endpoint of the international, open-label trial is progression-free survival (PFS). Secondary endpoints include overall response rate (ORR), duration of response, overall survival (OS), patient-reported outcomes and safety...